nach oben

Cancer Chemotherapy and Pharmacology

Erschienen in:

01.04.2014 | Review Article

Therapy resistance mechanisms in Ewing’s sarcoma family tumors

verfasst von: Atif A. Ahmed, Hamid Zia, Lars Wagner

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Ewing’s sarcoma family tumors are aggressive small round cell malignancies that arise in bone or soft tissues in adolescents and young adults. The addition of chemotherapy to local control measures has remarkably improved the survival of patients with localized disease. However, metastatic tumors are often refractory to conventional chemotherapy and irradiation, and the outcome of patients with metastatic or recurrent disease remains dismal. Despite growing understanding of the molecular biology of this tumor and the discovery of new therapeutic targets such as the insulin growth factor-1 receptor, tumor resistance continues to be a formidable challenge. Numerous adaptive mechanisms have been identified which allow tumor cells to escape the cytotoxic effect of chemotherapeutic agents. This review focuses on these mechanisms in an effort to highlight opportunities for more effective disease control.

Balamuth NJ, Womer RB (2010) Ewing’s sarcoma. Lancet Oncol 11(2):184–192PubMedCrossRef

Ross KA, Smyth NA, Murawski CD, Kennedy JG (2013) The biology of Ewing sarcoma. ISRN Oncol 2013:759725PubMedCentralPubMed

Kelleher FC, Thomas DM (2012) Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours. Clin Sarcoma Res 2(1):6PubMedCentralPubMedCrossRef

Ordóñez JL, Osuna D, Herrero D, de Alava E, Madoz-Gúrpide J (2009) Advances in Ewing’s sarcoma research: where are we now and what lies ahead? Cancer Res 69(18):7140–7150PubMedCrossRef

Grier HE (1997) The Ewing family of tumors. Ewing’s sarcoma and primitive neuroectodermal tumors. Pediatr Clin North Am 44:991PubMedCrossRef

Kissane JM, Askin FB, Foulkes M, Stratton LB, Shirley SF (1983) Ewing’s sarcoma of bone: clinicopathologic aspects of 303 cases from the Intergroup Ewing’s Sarcoma Study. Hum Pathol 14:773PubMedCrossRef

Arpaci E, Yetisyigit T, Seker M, Uncu D, Uyeturk U, Oksuzoglu B, Demirci U, Coskun U, Kucukoner M, Isıkdogan A, Inanc M, Alkis N, Ozkan M (2013) Prognostic factors and clinical outcome of patients with Ewing’s sarcoma family of tumors in adults: multicentric study of the Anatolian Society of Medical Oncology. Med Oncol 30(1):469PubMedCrossRef

Geryk-Hall M, Hughes DP (2009) Critical signaling pathways in bone sarcoma: candidates for therapeutic interventions. Curr Oncol Rep 11(6):446–453PubMedCrossRef

Johnson R, Humphreys SR (1969) Past failures and future possibilities in Ewing’s sarcoma: experimental and preliminary clinical results. Cancer 23:161–166PubMedCrossRef

10.

Womer RB, West DC, Krailo MD, Dickman PS, Pawel BR, Grier HE, Marcus K, Sailer S, Healey JH, Dormans JP, Weiss AR (2012) Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol 30:4148–4154PubMedCentralPubMedCrossRef

11.

Rodriguez-Galindo C, Billups CA, Kun LE, Rao BN, Pratt CB, Merchant TE, Santana VM, Pappo AS (2002) Survival after recurrence of Ewing tumors: the St Jude Children’s Research Hospital experience, 1979–1999. Cancer 94:561–569PubMedCrossRef

12.

Pinkerton CR, Bataillard A, Guillo S, Oberlin O, Fervers B, Philip T (2001) Treatment strategies for metastatic Ewing’s sarcoma. Eur J Cancer 37:1338–1344PubMedCrossRef

13.

Bao B, Ahmad A, Azmi AS, Ali S, Sarkar FH (2013) Overview of cancer stem cells (CSCs) and mechanisms of their regulation: implications for cancer therapy. Curr Protoc Pharmacol 14(Unit14):25PubMed

14.

Honoki K (2010) Do stem-like cells play a role in drug resistance of sarcomas? Expert Rev Anticancer Ther 10(2):261–270PubMedCrossRef

15.

Bao B, Ahmad A, Li Y, Azmi AS, Ali S, Banerjee S, Kong D, Sarkar FH (2012) Targeting CSCs within the tumor microenvironment for cancer therapy: a potential role of mesenchymal stem cells. Expert Opin Ther Targets 16(10):1041–1054PubMedCrossRef

16.

Trucco M, Loeb D (2012) Sarcoma stem cells: do we know what we are looking for? Sarcoma 2012:291705PubMedCentralPubMedCrossRef

17.

Monument MJ, Bernthal NM, Randall RL (2013) Salient features of mesenchymal stem cells-implications for Ewing sarcoma modeling. Front Oncol 3:24PubMedCentralPubMedCrossRef

18.

Lin PP, Wang Y, Lozano G (2011) Mesenchymal stem cells and the origin of Ewing’s sarcoma. Sarcoma 2011:276463

19.

Jiang X, Gwye Y, Russell D, Cao C, Douglas D, Hung L, Kovar H, Triche TJ, Lawlor ER (2010) CD133 expression in chemo-resistant Ewing sarcoma cells. BMC Cancer 10:116PubMedCentralPubMedCrossRef

20.

Saini V, Shoemaker RH (2010) Potential for therapeutic targeting of tumor stem cells. Cancer Sci 101(1):16–21PubMedCrossRef

21.

Huang HY, Illei PB, Zhao Z, Mazumdar M, Huvos AG, Healey JH, Wexler LH, Gorlick R, Meyers P, Ladanyi M (2005) Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol 23(3):548–558PubMedCrossRef

22.

Lopez-Guerrero JA, Machado I, Scotlandi K, Noguera R, Pellin A, Navarro S, Serra M, Calabuig-Fariñas S, Picci P, Llombart-Bosch A (2011) Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewing’s sarcoma family of tumors. Int J Cancer 128:1139–1150PubMedCrossRef

23.

Dylla L, Moore C, Jedlicka P (2013) MicroRNAs in Ewing sarcoma. Front Oncol 3:65PubMedCentralPubMedCrossRef

24.

Iida K, Fukushi J, Matsumoto Y, Oda Y, Takahashi Y, Fujiwara T, Fujiwara-Okada Y, Hatano M, Nabashima A, Kamura S, Iwamoto Y (2013) miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor. Cancer Cell Int 13(1):21PubMedCentralPubMedCrossRef

25.

Nakatani F, Ferracin M, Manara MC, Ventura S, Del Monaco V, Ferrari S, Alberghini M, Grilli A, Knuutila S, Schaefer KL, Mattia G, Negrini M, Picci P, Serra M, Scotlandi K (2012) miR-34a predicts survival of Ewing’s sarcoma patients and directly influences cell chemo-sensitivity and malignancy. J Pathol 226(5):796–805PubMedCrossRef

26.

Robin TP, Smith A, McKinsey E, Reaves L, Jedlicka P, Ford HL (2012) EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance. Mol Cancer Res 10(8):1098–1108PubMedCentralPubMedCrossRef

27.

Navarro S, Giraudo P, Karseladze AI, Smirnov A, Petrovichev N, Savelov N, Alvarado-Cabrero I, Llombart-Bosch A (2007) Immunophenotypic profile of biomarkers related to anti-apoptotic and neural development pathways in the Ewing’s family of tumors (EFT) and their therapeutic implications. Anticancer Res 27(4B):2457–2463PubMed

28.

Greve B, Sheikh-Mounessi F, Kemper B, Ernst I, Götte M, Eich HT (2012) Survivin, a target to modulate the radiosensitivity of Ewing’s sarcoma. Strahlenther Onkol 188(11):1038–1047PubMedCrossRef

29.

Holt SV, Brookes KE, Dive C, Makin GW (2011) Down-regulation of XIAP by AEG35156 in paediatric tumour cells induces apoptosis and sensitises cells to cytotoxic agents. Oncol Rep 25(4):1177–1181PubMed

30.

Mitsiades N, Poulaki V, Leone A, Tsokos M (1999) Fas-mediated apoptosis in Ewing’s sarcoma cell lines by metalloproteinase inhibitors. J Natl Cancer Inst 91(19):1678–1684PubMedCrossRef

31.

Hijazi YM, Axiotis CA, Navarro S, Steinberg SM, Horowitz ME, Tsokos M (1994) Immunohistochemical detection of P-glycoprotein in Ewing’s sarcoma and peripheral primitive neuroectodermal tumors before and after chemotherapy. Am J Clin Pathol 102(1):61–67PubMed

32.

Oda Y, Dockhorn-Dworniczak B, Jürgens H, Roessner A (1997) Expression of multidrug resistance-associated protein gene in Ewing’s sarcoma and malignant peripheral neuroectodermal tumor of bone. J Cancer Res Clin Oncol 123(4):237–239PubMedCrossRef

33.

Okada T, Tanaka K, Nakatani F, Sakimura R, Matsunobu T, Li X, Hanada M, Nakamura T, Oda Y, Tsuneyoshi M, Iwamoto Y (2006) Involvement of P-glycoprotein and MRP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing’s sarcoma cells. Int J Cancer 118(1):90–97PubMedCrossRef

34.

Januchowski R, Wojtowicz K, Zabel M (2013) The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance. Biomed Pharmacother 67(7):669–680

35.

Awad O, Yustein JT, Shah P, Gul N, Katuri V, O’Neill A, Kong Y, Brown ML, Toretsky JA, Loeb DM (2010) High ALDH activity identifies chemotherapy-resistant Ewing’s sarcoma stem cells that retain sensitivity to EWS–FLI1 inhibition. PLoS One 5(11):e13943PubMedCentralPubMedCrossRef

36.

Nakamura T, Tanaka K, Matsunobu T, Okada T, Nakatani F, Sakimura R, Hanada M, Iwamoto Y (2007) The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing’s family tumor cells. Int J Oncol 31(4):803–811PubMed

37.

Townsend DM, Tew KD (2003) The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22(47):7369–7375PubMedCrossRef

38.

Pasello M, Manara MC, Michelacci F, Fanelli M, Hattinger CM, Nicoletti G, Landuzzi L, Lollini PL, Caccuri A, Picci P, Scotlandi K, Serra M (2011) Targeting glutathione-S transferase enzymes in musculoskeletal sarcomas: a promising therapeutic strategy. Anal Cell Pathol (Amst) 34(3):131–145

39.

Dhaini HR, Thomas DG, Giordano TJ, Johnson TD, Biermann JS, Leu K, Hollenberg PF, Baker LH (2003) Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma. J Clin Oncol 21(13):2481–2485PubMedCrossRef

40.

Scotlandi K (2006) Targeted therapies in Ewing’s sarcoma. Adv Exp Med Biol 587:13–22PubMedCrossRef

41.

Shukla N, Schiffman J, Reed D, Davis IJ, Womer RB, Lessnick SL, Lawlor ER (2013) COG Ewing Sarcoma Biology Committee. Biomarkers in Ewing sarcoma: the Promise and Challenge of Personalized Medicine. A report from the Children’s Oncology Group. Front Oncol 3:141PubMedCentralPubMedCrossRef

42.

van Maldegem AM, Hogendoorn PC, Hassan AB (2012) The clinical use of biomarkers as prognostic factors in Ewing sarcoma. Clin Sarcoma Res 2(1):7PubMedCentralPubMedCrossRef

43.

Rikhof B, de Jong S, Suurmeijer AJ, Meijer C, van der Graaf WT (2009) The insulin-like growth factor system and sarcomas. J Pathol 217(4):469–482PubMedCrossRef

44.

Olmos D, Martins AS, Jones RL, Alam S, Scurr M, Judson IR (2011) Targeting the insulin-like growth factor 1 receptor in Ewing’s sarcoma: reality and expectations. Sarcoma 2011:402508PubMedCentralPubMedCrossRef

45.

Manara MC, Perdichizzi S, Serra M, Pierini R, Benini S, Hattinger CM, Astolfi A, Bagnati R, D’Incalci M, Picci P, Scotlandi K (2005) The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing’s sarcoma cell line, TC-71. Int J Oncol 27(6):1605–1616PubMed

46.

Kolb EA, Gorlick R (2009) Development of IGF–IR inhibitors in pediatric sarcomas. Curr Oncol Rep 11(4):307–313PubMedCrossRef

47.

Olmos D, Tan DS, Jones RL, Judson IR (2010) Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside. Cancer J 16(3):183–194PubMedCrossRef

48.

O’Neill A, Shah N, Zitomersky N, Ladanyi M, Shukla N, Uren A, Loeb D, Toretsky J (2013) Insulin-like growth factor 1 receptor as a therapeutic target in Ewing sarcoma: lack of consistent upregulation or recurrent mutation and a review of the clinical trial literature. Sarcoma 2013:450478PubMedCentralPubMed

49.

Garofalo C, Mancarella C, Grilli A, Manara MC, Astolfi A, Marino MT, Conte A, Sigismund S, Carè A, Belfiore A, Picci P, Scotlandi K (2012) Identification of common and distinctive mechanisms of resistance to different anti-IGF–IR agents in Ewing’s sarcoma. Mol Endocrinol 26(9):1603–1616PubMedCrossRef

50.

Garofalo C, Manara MC, Nicoletti G, Marino MT, Lollini PL, Astolfi A, Pandini G, López-Guerrero JA, Schaefer KL, Belfiore A, Picci P, Scotlandi K (2011) Efficacy of and resistance to anti-IGF-1R therapies in Ewing’s sarcoma is dependent on insulin receptor signaling. Oncogene 30(24):2730–2740PubMedCrossRef

51.

Ahmed AA, Sherman AK, Pawel BR (2012) Expression of therapeutic targets in Ewing sarcoma family tumors. Hum Pathol 43(7):1077–1083PubMedCrossRef

52.

Chandhanayingyong C, Kim Y, Staples JR, Hahn C, Lee FY (2012) MAPK/ERK signaling in osteosarcomas, Ewing sarcomas and chondrosarcomas: therapeutic implications and future directions. Sarcoma 2012:404810PubMedCentralPubMedCrossRef

53.

Liu C, Zhang Z, Tang H, Jiang Z, You L, Lia Y (2013) Crosstalk between IGF-1R and other tumor promoting pathways. Curr Pharm Des 19:1–10

54.

Wagner MJ, Maki RG (2013) Type 1 insulin-like growth factor receptor targeted therapies in pediatric cancer. Front Oncol 3:9PubMedCentralPubMedCrossRef

55.

Mendoza-Naranjo A, El-Naggar A, Wai DH, Mistry P, Lazic N, Ayala FR, da Cunha IW, Rodriguez-Viciana P, Cheng H, Tavares Guerreiro Fregnani JH, Reynolds P, Arceci RJ, Nicholson A, Triche TJ, Soares FA, Flanagan AM, Wang YZ, Strauss SJ, Sorensen PH (2013) ERBB4 confers metastatic capacity in Ewing sarcoma. EMBO Mol Med 5(7):1019–1034PubMedCentralPubMedCrossRef

56.

Li L, Tibiche C, Fu C, Kaneko T, Moran MF, Schiller MR, Li SS, Wang E (2012) The human phosphotyrosine signaling network: evolution and hotspots of hijacking in cancer. Genome Res 22(7):1222–1230PubMedCentralPubMedCrossRef

57.

Diaz-Cano SalvadorJ (2012) Tumor heterogeneity: mechanisms and bases for a reliable application of molecular marker design. Int J Mol Sci 13(2):1951–2011PubMedCentralPubMedCrossRef

58.

Fisher R, Pusztai L, Swanton C (2013) Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer 108(3):479–485PubMedCentralPubMedCrossRef

59.

Kurmasheva RT, Dudkin L, Billups C, Debelenko LV, Morton CL, Houghton PJ (2009) The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res 69(19):7662–7671PubMedCentralPubMedCrossRef

60.

Naing A, LoRusso P, Fu S, Hong DS, Anderson P, Benjamin RS, Ludwig J, Chen HX, Doyle LA, Kurzrock R (2012) Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing’s sarcoma family tumors. Clin Cancer Res 18(9):2625–2631PubMedCrossRef

61.

Huang S, Kauffman S (2013) How to escape the cancer attractor: rationale and limitations of multi-target drugs. Semin Cancer Biol 23(4):270–278

62.

Huang S, Ernberg I, Kauffman S (2009) Cancer attractors: a systems view of tumors from a gene network dynamics and developmental perspective. Semin Cell Dev Biol 20(7):869–876PubMedCentralPubMedCrossRef

63.

Csermely P, Korcsmáros T (2013) Cancer-related networks: a help to understand, predict and change malignant transformation. Semin Cancer Biol 23(4):209–212

64.

Subbiah V, Kurzrock R (2012) Ewing’s sarcoma: overcoming the therapeutic plateau. Discov Med 13(73):405–415PubMedCentralPubMed

Titel: Therapy resistance mechanisms in Ewing’s sarcoma family tumors
verfasst von: Atif A. Ahmed
Hamid Zia
Lars Wagner
Publikationsdatum: 01.04.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 4/2014
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-014-2392-1

Springer Medizin

Therapy resistance mechanisms in Ewing’s sarcoma family tumors

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Simvastatin suppresses head and neck squamous cell carcinoma ex vivo and enhances the cytostatic effects of chemotherapeutics

Clinical pharmacokinetics of Icotinib, an anti-cancer drug: evaluation of dose proportionality, food effect, and tolerability in healthy subjects

Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS

Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors

The impact of dose/time modification in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancer

A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie